A carregar...

The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors

Since the discovery of the Jak2-V617F mutation as the causative agent in a large number of myeloproliferative neoplasms (MPNs), there has been a drive to develop Jak2 specific inhibitors that can be used in therapy for MPN patients and other Jak2-related pathologies. Over the past few years, a numbe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baskin, Rebekah, Majumder, Anurima, Sayeski, Peter P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3636533/
https://ncbi.nlm.nih.gov/pubmed/21062251
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!